Paratek Pharmaceuticals Current Ratio 2006-2021 | PRTK

Paratek Pharmaceuticals current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Paratek Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.15B $0.02B 7.32
2021-03-31 $0.14B $0.02B 6.18
2020-12-31 $0.16B $0.02B 6.85
2020-09-30 $0.20B $0.02B 8.52
2020-06-30 $0.22B $0.03B 6.55
2020-03-31 $0.23B $0.04B 5.27
2019-12-31 $0.24B $0.02B 10.06
2019-09-30 $0.25B $0.03B 9.80
2019-06-30 $0.27B $0.02B 12.17
2019-03-31 $0.27B $0.02B 14.06
2018-12-31 $0.26B $0.02B 14.41
2018-09-30 $0.29B $0.03B 11.38
2018-06-30 $0.27B $0.03B 7.88
2018-03-31 $0.19B $0.02B 8.06
2017-12-31 $0.16B $0.02B 9.56
2017-09-30 $0.17B $0.02B 10.52
2017-06-30 $0.18B $0.02B 11.88
2017-03-31 $0.14B $0.02B 7.66
2016-12-31 $0.13B $0.02B 6.47
2016-09-30 $0.13B $0.02B 5.86
2016-06-30 $0.16B $0.03B 5.45
2016-03-31 $0.12B $0.03B 4.59
2015-12-31 $0.14B $0.02B 6.95
2015-09-30 $0.16B $0.01B 11.39
2015-06-30 $0.15B $0.01B 13.55
2015-03-31 $0.09B $0.01B 12.91
2014-12-31 $0.10B $0.00B 27.09
2014-09-30 $0.04B $0.00B 13.96
2014-06-30 $0.04B $0.00B 17.79
2014-03-31 $0.07B $0.00B 36.86
2013-12-31 $0.00B $0.04B 0.04
2013-09-30 $0.08B $0.00B 25.91
2013-06-30 $0.08B $0.00B 60.13
2013-03-31 $0.09B $0.00B 40.20
2012-12-31 $0.10B $0.00B 35.66
2012-09-30 $0.10B $0.00B 30.04
2012-06-30 $0.10B $0.00B 30.56
2012-03-31 $0.06B $0.00B 23.62
2011-12-31 $0.07B $0.00B 19.72
2011-09-30 $0.06B $0.00B 23.62
2011-06-30 $0.06B $0.00B 16.36
2011-03-31 $0.07B $0.01B 10.30
2010-12-31 $0.07B $0.01B 7.20
2010-09-30 $0.08B $0.01B 5.45
2010-06-30 $0.08B $0.02B 5.27
2010-03-31 $0.09B $0.02B 5.62
2009-12-31 $0.09B $0.02B 5.62
2009-09-30 $0.10B $0.02B 6.07
2009-06-30 $0.08B $0.00B 20.19
2009-03-31 $0.08B $0.01B 17.71
2008-12-31 $0.01B $0.01B 2.28
2008-09-30 $0.09B $0.01B 19.95
2008-06-30 $0.10B $0.01B 19.70
2008-03-31 $0.10B $0.06B 1.74
2007-12-31 $0.11B $0.02B 5.62
2007-09-30 $0.11B $0.02B 5.85
2007-06-30 $0.11B $0.02B 5.00
2007-03-31 $0.06B $0.01B 7.39
2006-12-31 $0.07B $0.01B 10.53
2006-09-30 $0.07B $0.01B 11.85
2006-06-30 $0.08B $0.01B 12.85
2006-03-31 $0.05B $0.01B 7.21
2005-12-31 $0.05B $0.01B 11.05
2005-09-30 $0.00B 0.00
2005-06-30 $0.00B 0.00
2005-03-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.244B $0.047B
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00